In a report released today, Roger Song from Jefferies maintained a Buy rating on Novavax (NVAX – Research Report), with a price target of ...

On Friday, Novavax Inc (NVAX) stock saw a modest uptick, ending the day at $13.3 which represents a slight increase of $1.15 or 9.47% from the prior close of $12.15. The stock opened at $12.32 and ...

Shares of Novavax Inc. NVAX shed 5.04% to $12.63 Monday, on what proved to be an all-around great trading session for the ...

In addition to Pfizer and Moderna's new formulas, Novavax's protein-based shot is an option for COVID vaccination this season ...

Novavax (NVAX) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

TORONTO — The Public Health Agency of Canada says it is not providing Novavax’s COVID-19 vaccine this respiratory virus ...

Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store. Novavax, Inc. (Nasdaq: NVAX), a global company ...

The Public Health Agency of Canada says a very small portion of the doses ordered in 2023 were used and that its decision reflects efforts to limit vaccine wastage.

On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.8 which represents a decrease of $-0.11 or -0.85% from the prior close of $12.91. The stock opened at $13.01 and touched a low ...

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Novavax Inc. closed $10.57 below its 52-week high ($23.86), which the company reached on June 6th.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Ruxandra Draghia-Akli, MD, PhD, will join the Company in ...